Skin | |||||
---|---|---|---|---|---|
Skin / Gustatory sweating | |||||
propantheline bromide | Hospital only | ||||
Skin / Hyperhidrosis | |||||
aluminium chloride hexahydrate | Joint formulary choice | ||||
Liquid | |||||
Anhydrol (Dermal Laboratories Ltd) | Joint formulary choice | ||||
botulinum toxin type A | Hospital only |
NICE TA260 NICE TA605 |
|||
Powder for solution for injection | |||||
Azzalure (Galderma (UK) Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
Bocouture (Merz Pharma UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
Botox (AbbVie Ltd) | Hospital only | ||||
Dysport (Ipsen Ltd) | Hospital only | ||||
Xeomin (Merz Pharma UK Ltd) | Hospital only | ||||
glycopyrronium bromide | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
Skin / Scalp and hair conditions | |||||
benzalkonium chloride | Not approved for prescribing | ||||
Shampoo | |||||
Dermax (Dermal Laboratories Ltd) | Not approved for prescribing | ||||
cetrimide with undecenoic acid | Not approved for prescribing | ||||
coal tar | Joint formulary choice | ||||
Shampoo | |||||
Coal tar (Non-proprietary) | Joint formulary choice | ||||
Neutrogena T/Gel Therapeutic (Johnson & Johnson Ltd) | Joint formulary choice | ||||
Polytar Scalp (Thornton & Ross Ltd) | Joint formulary choice | ||||
Cutaneous emulsion | |||||
Exorex (Teva UK Ltd) | Joint formulary choice | ||||
coal tar with salicylic acid and precipitated sulfur | Joint formulary choice | ||||
ketoconazole | Joint formulary choice | ||||
Shampoo | |||||
Ketoconazole (Non-proprietary) | Joint formulary choice | ||||
Dandrazol (Transdermal Ltd) | Joint formulary choice | ||||
Nizoral (Thornton & Ross Ltd) | Joint formulary choice | ||||
selenium | Joint formulary choice | ||||
Skin / Alopecia | |||||
finasteride | Not approved for prescribing | ||||
minoxidil | Not approved for prescribing | ||||
Liquid | |||||
Minoxidil (Non-proprietary) | Not approved for prescribing | ||||
Regaine (Johnson & Johnson Ltd, McNeil Products Ltd) | Not approved for prescribing | ||||
Skin / Hirsutism | |||||
co-cyprindiol | Joint formulary choice | ||||
eflornithine | Not approved for prescribing | ||||
Skin / Superficial soft-tissue injuries and superficial thrombophlebitis | |||||
heparinoid | Not approved for prescribing | ||||
Skin / Dry and scaling skin disorders | |||||
barrier creams and ointments | |||||
Cutaneous cream | |||||
Sudocrem (Teva UK Ltd) | Joint formulary choice | ||||
emollient bath and shower products, antimicrobial-containing | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Bath additive | |||||
Dermol 600 (Dermal Laboratories Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Emulsiderm (Dermal Laboratories Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Oilatum Plus (Thornton & Ross Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
emollient bath and shower products, paraffin-containing | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Bath additive | |||||
Emollient bath and shower products, paraffin-containing (Non-proprietary) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Dermalo (Dermal Laboratories Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Doublebase (Dermal Laboratories Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Zerolatum (Thornton & Ross Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Form unstated | |||||
E45 emollient bath (Karo Pharma UK Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Products without form | |||||
Emollient bath and shower products, paraffin-containing (Non-proprietary) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Cutaneous wash | |||||
Emollient bath and shower products, paraffin-containing (Non-proprietary) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
E45 emollient wash (Karo Pharma UK Ltd) | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
emollient bath and shower products, soya-bean oil-containing | Not approved for prescribing | ||||
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances
Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient). |
|||||
Bath additive | |||||
Zeroneum (Thornton & Ross Ltd) | Not approved for prescribing | ||||
emollient creams and ointments, antimicrobial-containing | Joint formulary choice | ||||
emollient creams and ointments, colloidal oatmeal-containing | Joint formulary choice | ||||
Form unstated | |||||
Emollient creams and ointments, colloidal oatmeal-containing (Non-proprietary) | Joint formulary choice | ||||
emollient creams and ointments, paraffin-containing | Joint formulary choice | ||||
Liquid | |||||
Emollient creams and ointments, paraffin-containing (Non-proprietary) | Joint formulary choice | ||||
Spray | |||||
Emollin (C D Medical Ltd) | Joint formulary choice | ||||
Products without form | |||||
Adex (Dermal Laboratories Ltd) | Joint formulary choice | ||||
Joint Prescribing Group's decision
June 2019 - the JPG agreed to approved the addition of Adex® gel to the joint formulary for dry skin conditions associated with inflammation and redness that would benefit from a steroid-free emollient with an added anti-inflammatory effect. |
|||||
emollients, urea-containing | Joint formulary choice | ||||
Products without form | |||||
Emollients, urea-containing (Non-proprietary) | Not approved for prescribing | ||||
Dermatonics Once (Dermatonics Ltd) | Joint formulary choice | ||||
Flexitol (Thornton & Ross Ltd) | Joint formulary choice | ||||
Skin / Acne | |||||
adapalene | Joint formulary choice | ||||
adapalene with benzoyl peroxide | Joint formulary choice | ||||
Joint Prescribing Group's decision
May 2019 - the JPG agreed to approved the addition of Epiduo® (adapalene and benzoyl peroxide gel) to the joint formulary for acne vulgaris. |
|||||
azelaic acid | Joint formulary choice | ||||
benzoyl peroxide | Joint formulary choice | ||||
benzoyl peroxide with clindamycin | Joint formulary choice | ||||
clindamycin | Joint formulary choice | ||||
co-cyprindiol | Joint formulary choice | ||||
doxycycline | Joint formulary choice | ||||
Modified-release capsule | |||||
Efracea (Galderma (UK) Ltd) | Joint formulary choice | ||||
erythromycin with zinc acetate | Joint formulary choice | ||||
Liquid | |||||
Zineryt (Neon Healthcare Ltd) | Joint formulary choice | ||||
isotretinoin | Hospital only | ||||
lymecycline | Joint formulary choice | ||||
minocycline | Not approved for prescribing | ||||
Modified-release capsule | |||||
Acnamino MR (Dexcel-Pharma Ltd) | Not approved for prescribing | ||||
Minocin MR (Viatris UK Healthcare Ltd) | Not approved for prescribing | ||||
nicotinamide | Not approved for prescribing | ||||
oxytetracycline | Joint formulary choice | ||||
tretinoin with clindamycin | Joint formulary choice | ||||
tretinoin with erythromycin | Not approved for prescribing | ||||
Liquid | |||||
Aknemycin Plus (Almirall Ltd) | Not approved for prescribing | ||||
Skin / Rosacea | |||||
azelaic acid | Joint formulary choice | ||||
brimonidine tartrate | Not approved for prescribing | ||||
ivermectin | Joint formulary choice | ||||
Skin / Sun protection and photodamage | |||||
fluorouracil | Not approved for prescribing | ||||
fluorouracil with salicylic acid | Not approved for prescribing | ||||
Cutaneous solution | |||||
Actikerall (Almirall Ltd) | Not approved for prescribing | ||||
ingenol mebutate | Not approved for prescribing | ||||
tirbanibulin | Hospital only | ||||
North East London Formulary & Pathways Group’s Decision – Tirbanibulin ointment for treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis of the face or scalp in adults
November 2023 - The North East London Formulary & Pathways Group (FPG) approved tirbanibulin ointment for treatment of non-hyperkeratotic, non-hypertrophic (Olsen grade 1) actinic keratosis of the face or scalp in adults. This treatment should only be prescribed by a dermatology specialist as:
GPs could gain support via Advice & Guidance (A&G) and refer patients back to secondary care clinicians if discharged patients attended the practice with treatment concerns.
|
|||||
Cutaneous ointment | |||||
Klisyri (Almirall Ltd) | Hospital only | ||||
Skin / Warts and calluses | |||||
camellia sinensis | Hospital only | ||||
formaldehyde | Not approved for prescribing | ||||
Liquid | |||||
Formaldehyde (Non-proprietary) | Not approved for prescribing | ||||
imiquimod | Joint formulary choice | ||||
podophyllotoxin | Joint formulary choice | ||||
Liquid | |||||
Warticon (Phoenix Labs Ltd) | Joint formulary choice | ||||
salicylic acid | Joint formulary choice | ||||
Liquid | |||||
Occlusal (Alliance Pharmaceuticals Ltd) | Joint formulary choice | ||||
salicylic acid with lactic acid | Joint formulary choice | ||||
Cutaneous paint | |||||
Duofilm (Thornton & Ross Ltd) | Joint formulary choice | ||||
Salactol (Dermal Laboratories Ltd) | Not approved for prescribing | ||||
silver nitrate | Hospital only | ||||
Skin / Eczema and psoriasis | |||||
abrocitinib | Hospital only |
NICE TA814 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
Oral tablet | |||||
Cibinqo (Pfizer Ltd) | Hospital only | ||||
acitretin | Hospital only | ||||
adalimumab | Hospital only |
NICE TA187 NICE TA329 NICE TA199 NICE TA195 NICE TA375 NICE TA715 NICE TA383 NICE TA392 NICE TA146 NICE TA460 |
|||
North East London Formulary & Pathways Group’s Decision - Adalimumab escalated dosing for psoriasis
October 2023 - The North East London Formulary & Pathways Group (FPG) approved the use of Adalimumab escalated dose for moderate to severe plaque psoriasis in adult patients who have inadequate reqponse to standard dosing. Approved escalated maintenance dose: 40mg once weekly (or 80mg every 2 weeks if reduced frequency of dosing required). |
|||||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Humira (AbbVie Ltd) | Hospital only | ||||
ADALIMUMAB
Dose escalation of Adalimumab is approved for Crohn's disease and ulcerative colitis |
|||||
alclometasone dipropionate | Not approved for prescribing | ||||
alitretinoin | Hospital only |
NICE TA177 |
|||
apremilast | Hospital only |
NICE TA433 NICE TA419 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
azathioprine | Shared care guideline | ||||
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
baricitinib | Hospital only |
NICE TA466 NICE TA681 NICE TA926 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
beclometasone dipropionate | Not approved for prescribing | ||||
betamethasone | Joint formulary choice | ||||
North East London Formulary & Pathways Group's Decision
November 2022 - The North East London Formulary & Pathways Group (FPG) approved the use of Betesil® (Betamethasone valerate) 2.25mg medicated plasters. This is indicated for the treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides. Formulary status: Amber (specialist knowledge/initiation) - to be initiated by or on recommendation of a dermatologist or GPwSI in dermatology. |
|||||
Liquid | |||||
Betacap (Dermal Laboratories Ltd) | Joint formulary choice | ||||
Betnovate (GlaxoSmithKline UK Ltd) | Joint formulary choice | ||||
Diprosone (Organon Pharma (UK) Ltd) | Joint formulary choice | ||||
Medicated plaster | |||||
Betesil (Derma UK Ltd) | Specialist knowledge/initiation | ||||
North East London Formulary & Pathways Group's Decision
November 2022 - The North East London Formulary & Pathways Group (FPG) approved the use of Betesil® (Betamethasone valerate) 2.25mg medicated plasters. This is indicated for the treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides. Formulary status: Amber (specialist knowledge/initiation) - to be initiated by or on recommendation of a dermatologist or GPwSI in dermatology. |
|||||
betamethasone with clioquinol | Joint formulary choice | ||||
betamethasone with clotrimazole | Joint formulary choice | ||||
betamethasone with fusidic acid | Joint formulary choice | ||||
betamethasone with neomycin | Joint formulary choice | ||||
betamethasone with salicylic acid | Joint formulary choice | ||||
Liquid | |||||
Diprosalic (Organon Pharma (UK) Ltd) | Joint formulary choice | ||||
bimekizumab | Hospital only |
NICE TA723 NICE TA916 NICE TA918 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Bimzelx (UCB Pharma Ltd) | Hospital only | ||||
brodalumab | Hospital only |
NICE TA511 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Kyntheum (LEO Pharma) | Hospital only | ||||
calcipotriol | Joint formulary choice | ||||
Liquid | |||||
Calcipotriol (Non-proprietary) | Joint formulary choice | ||||
calcipotriol with betamethasone | Joint formulary choice | ||||
calcitriol | Joint formulary choice | ||||
certolizumab pegol | Hospital only |
NICE TA375 NICE TA383 NICE TA415 NICE TA445 NICE TA574 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Cimzia (UCB Pharma Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
ciclosporin | Shared care guideline |
NICE TA369 |
|||
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
Oral solution | |||||
Neoral (Novartis Pharmaceuticals UK Ltd) | Shared care guideline | ||||
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
Sandimmun (Novartis Pharmaceuticals UK Ltd) | Shared care guideline | ||||
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
Solution for infusion | |||||
Sandimmun (Novartis Pharmaceuticals UK Ltd) | Hospital only | ||||
clobetasol propionate | Joint formulary choice | ||||
Liquid | |||||
Dermovate (GlaxoSmithKline UK Ltd) | Joint formulary choice | ||||
Shampoo | |||||
Etrivex (Galderma (UK) Ltd) | Joint formulary choice | ||||
clobetasol propionate with neomycin sulfate and nystatin | Specialist knowledge/initiation | ||||
clobetasone butyrate | Joint formulary choice | ||||
clobetasone butyrate with nystatin and oxytetracycline | Joint formulary choice | ||||
coal tar | Joint formulary choice | ||||
Cutaneous emulsion | |||||
Exorex (Teva UK Ltd) | Joint formulary choice | ||||
coal tar with calamine | Not approved for prescribing | ||||
coal tar with coconut oil and salicylic acid | Joint formulary choice | ||||
Shampoo | |||||
Capasal (Dermal Laboratories Ltd) | Joint formulary choice | ||||
coal tar with dithranol and salicylic acid | Not approved for prescribing | ||||
coal tar with salicylic acid | Not approved for prescribing | ||||
coal tar with salicylic acid and precipitated sulfur | Joint formulary choice | ||||
coal tar with zinc oxide | Not approved for prescribing | ||||
deucravacitinib | Hospital only |
NICE TA907 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Oral tablet | |||||
Sotyktu (Bristol-Myers Squibb Pharmaceuticals Ltd) | Hospital only | ||||
dimethyl fumarate | Hospital only | ||||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Skilarence® NICE TA475 Tecfidera® NICE TA320 |
|||||
Gastro-resistant tablet | |||||
Skilarence (Almirall Ltd) | Hospital only | ||||
dithranol | Specialist knowledge/initiation | ||||
dithranol with salicylic acid and zinc oxide | Not approved for prescribing | ||||
dupilumab | Hospital only |
NICE TA534 NICE TA751 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Dupixent (Sanofi) | Hospital only | ||||
etanercept | Hospital only |
NICE TA103 NICE TA195 NICE TA375 NICE TA715 NICE TA199 NICE TA383 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Biosimilar preparation is available for this
Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept |
|||||
Solution for injection | |||||
Benepali (Biogen Idec Ltd) | Hospital only | ||||
Biosimilar preparation is available for this
Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept |
|||||
Enbrel (Pfizer Ltd) | Hospital only | ||||
Biosimilar preparation is available for this
Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept |
|||||
Enbrel MyClic (Pfizer Ltd) | Hospital only | ||||
Biosimilar preparation is available for this
Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept |
|||||
Erelzi (Sandoz Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
Biosimilar preparation is available for this
Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept |
|||||
Powder and solvent for solution for injection | |||||
Enbrel (Pfizer Ltd) | Hospital only | ||||
Biosimilar preparation is available for this
Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept |
|||||
fludroxycortide | Joint formulary choice | ||||
Impregnated dressing | |||||
Fludroxycortide (Non-proprietary) | Specialist knowledge/initiation | ||||
fluocinolone acetonide | Joint formulary choice |
NICE TA301 NICE TA613 NICE TA590 |
|||
fluocinonide | Joint formulary choice | ||||
fluticasone | Not approved for prescribing | ||||
guselkumab | Hospital only |
NICE TA521 NICE TA815 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Tremfya (Janssen-Cilag Ltd) | Hospital only | ||||
hydrocortisone | Joint formulary choice | ||||
hydrocortisone butyrate | Joint formulary choice | ||||
Liquid | |||||
Locoid (Neon Healthcare Ltd) | Joint formulary choice | ||||
hydrocortisone with benzalkonium chloride, dimeticone and nystatin | Joint formulary choice | ||||
hydrocortisone with chlorhexidine hydrochloride and nystatin | Not approved for prescribing | ||||
hydrocortisone with clotrimazole | Joint formulary choice | ||||
hydrocortisone with fusidic acid | Joint formulary choice | ||||
hydrocortisone with miconazole | Joint formulary choice | ||||
hydrocortisone with oxytetracycline | Not approved for prescribing | ||||
ichthammol | Not approved for prescribing | ||||
ichthammol with zinc oxide | Specialist knowledge/initiation | ||||
Impregnated dressing | |||||
Ichthopaste (Evolan Pharma AB) | Not approved for prescribing | ||||
infliximab | Hospital only |
NICE TA134 NICE TA195 NICE TA375 NICE TA715 NICE TA199 NICE TA187 NICE TA163 NICE TA329 NICE TA383 |
|||
Biosimilar
Remsima® (biosimilar infliximab) is the formulary choice brand for infliximab. |
|||||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Remsima (Celltrion Healthcare UK Ltd) | Hospital only | ||||
ixekizumab | Hospital only |
NICE TA442 NICE TA537 NICE TA718 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Taltz (Eli Lilly and Company Ltd) | Hospital only | ||||
methotrexate | Shared care guideline | ||||
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
Oral solution | |||||
Methotrexate (Non-proprietary) | Shared care guideline | ||||
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
Solution for injection | |||||
Methotrexate (Non-proprietary) | Hospital only | ||||
Metoject PEN (medac UK) | Hospital only | ||||
Nordimet (Nordic Pharma Ltd) | Hospital only | ||||
Zlatal (Nordic Pharma Ltd) | Hospital only | ||||
Solution for infusion | |||||
Methotrexate (Non-proprietary) | Hospital only | ||||
mometasone furoate | Joint formulary choice | ||||
Liquid | |||||
Elocon (Organon Pharma (UK) Ltd) | Joint formulary choice | ||||
pimecrolimus | Joint formulary choice |
NICE TA82 |
|||
risankizumab | Hospital only |
NICE TA596 NICE TA803 NICE TA888 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Skyrizi (AbbVie Ltd) | Hospital only | ||||
secukinumab | Hospital only |
NICE TA350 NICE TA407 NICE TA719 NICE TA445 NICE TA935 |
|||
Dose escalation of secukinumab for severe chronic plaque psoriasis
April 2023 - The North East London Formulary & Pathways Group approved use of Secukinumab at increased dosing freequency of 300mg every 2 weeks for patients with severe chronic plaque psoriasis who have secondary failure (as per NICE's description) with a body weight of 90kg or higher. Patients who have an inadequate response after 3 months of dose escalation should be offered alternative treatment as per the NEL High Cost Drug Psoriasis Pathway. |
|||||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Cosentyx (Novartis Pharmaceuticals UK Ltd) | Hospital only | ||||
tacalcitol | Joint formulary choice | ||||
tacrolimus | Joint formulary choice |
NICE TA82 NICE TA481 NICE TA481 |
|||
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
Modified-release tablet | |||||
Envarsus (Chiesi Ltd) | Not approved for prescribing | ||||
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
Modified-release capsule | |||||
Advagraf (Astellas Pharma Ltd) | Not approved for prescribing | ||||
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
Solution for infusion | |||||
Prograf (Astellas Pharma Ltd) | Not approved for prescribing | ||||
tildrakizumab | Hospital only |
NICE TA575 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
tralokinumab | Hospital only |
NICE TA814 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
Solution for injection | |||||
Adtralza (LEO Pharma) | Hospital only | ||||
upadacitinib | Hospital only |
NICE TA665 NICE TA744 NICE TA768 NICE TA829 NICE TA861 NICE TA814 NICE TA856 NICE TA905 |
|||
Modified-release tablet | |||||
Rinvoq (AbbVie Ltd) | Hospital only | ||||
ustekinumab | Hospital only |
NICE TA180 NICE TA340 NICE TA456 NICE TA633 |
|||
North East London Formulary & Pathways Group’s Decision – Ustekinumab dose escalation for moderate to severe psoriasis
June 2023 - The North East London Formulary & Pathways Group (FPG) approved dose escalation of ustekinumab for plaque psoriasis.
For use in patients with a waning response to maintenance dose of ustekinumab before next scheduled dose as quantified by the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) after full discussion at MDT. |
|||||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Stelara (Janssen-Cilag Ltd) | Hospital only | ||||
Solution for infusion | |||||
Stelara (Janssen-Cilag Ltd) | Hospital only | ||||
Skin / Urticaria | |||||
acrivastine | Not approved for prescribing | ||||
alimemazine tartrate | Not approved for prescribing | ||||
Oral solution | |||||
Alimemazine tartrate (Non-proprietary) | Not approved for prescribing | ||||
desloratadine | Not approved for prescribing | ||||
Oral solution | |||||
Desloratadine (Non-proprietary) | Not approved for prescribing | ||||
Neoclarityn (Organon Pharma (UK) Ltd) | Not approved for prescribing | ||||
fexofenadine hydrochloride | Joint formulary choice | ||||
levocetirizine hydrochloride | Not approved for prescribing | ||||
Oral solution | |||||
Xyzal (UCB Pharma Ltd) | Not approved for prescribing | ||||
loratadine | Joint formulary choice | ||||
Oral solution | |||||
Loratadine (Non-proprietary) | Joint formulary choice | ||||
Oral tablet | |||||
Loratadine (Non-proprietary) | Joint formulary choice | ||||
mizolastine | Not approved for prescribing | ||||
Modified-release tablet | |||||
Mizollen (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
omalizumab | Hospital only |
NICE TA278 NICE TA339 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
Solution for injection | |||||
Xolair (Novartis Pharmaceuticals UK Ltd) | Hospital only | ||||
promethazine hydrochloride | Joint formulary choice | ||||
Oral solution | |||||
Phenergan (Sanofi Consumer Healthcare) | Joint formulary choice | ||||
rupatadine | Not approved for prescribing | ||||
Skin / Skin cleansers, antiseptics and desloughing agents | |||||
alcohol | Not approved for prescribing | ||||
Form unstated | |||||
Alcohol (Non-proprietary) | Not approved for prescribing | ||||
chlorhexidine | Joint formulary choice | ||||
Liquid | |||||
Cepton (Dendron Brands Ltd) | Not approved for prescribing | ||||
Hibi (Molnlycke Health Care Ltd) | Joint formulary choice | ||||
Hibiscrub (Molnlycke Health Care Ltd) | Joint formulary choice | ||||
Hydrex (Ecolab Healthcare Division) | Joint formulary choice | ||||
chlorhexidine gluconate with isopropyl alcohol | Joint formulary choice | ||||
Liquid | |||||
ChloraPrep (Becton, Dickinson UK Ltd) | Joint formulary choice | ||||
chlorhexidine with cetrimide | Not approved for prescribing | ||||
diethyl phthalate with methyl salicylate | Not approved for prescribing | ||||
Liquid | |||||
Diethyl phthalate with methyl salicylate (Non-proprietary) | Not approved for prescribing | ||||
hydrogen peroxide | Joint formulary choice | ||||
Liquid | |||||
Hydrogen peroxide (Non-proprietary) | Joint formulary choice | ||||
Mouthwash | |||||
Peroxyl (Colgate-Palmolive (UK) Ltd) | Not approved for prescribing | ||||
potassium permanganate | Joint formulary choice | ||||
Tablet for cutaneous solution | |||||
Potassium permanganate (Non-proprietary) | Joint formulary choice | ||||
Permitabs (Alliance Pharmaceuticals Ltd) | Joint formulary choice | ||||
povidone-iodine | Joint formulary choice | ||||
Liquid | |||||
Videne (Ecolab Healthcare Division) | Joint formulary choice | ||||
proflavine | Not approved for prescribing | ||||
Skin / Minor cuts and abrasions | |||||
castor oil with collodion and colophony | Not approved for prescribing | ||||
glycerol with magnesium sulfate and phenol | Not approved for prescribing | ||||
Skin / Pruritus | |||||
alimemazine tartrate | Not approved for prescribing | ||||
Oral solution | |||||
Alimemazine tartrate (Non-proprietary) | Not approved for prescribing | ||||
calamine with zinc oxide | Not approved for prescribing | ||||
Liquid | |||||
Calamine with zinc oxide (Non-proprietary) | Not approved for prescribing | ||||
cetirizine hydrochloride | Joint formulary choice | ||||
Oral solution | |||||
Cetirizine hydrochloride (Non-proprietary) | Joint formulary choice | ||||
Oral tablet | |||||
Cetirizine hydrochloride (Non-proprietary) | Joint formulary choice | ||||
chlorphenamine maleate | Joint formulary choice | ||||
Oral solution | |||||
Chlorphenamine maleate (Non-proprietary) | Joint formulary choice | ||||
Allerief (Crescent Pharma Ltd) | Joint formulary choice | ||||
Piriton (Haleon UK Ltd) | Joint formulary choice | ||||
Solution for injection | |||||
Chlorphenamine maleate (Non-proprietary) | Hospital only | ||||
Oral tablet | |||||
Chlorphenamine maleate (Non-proprietary) | Joint formulary choice | ||||
coal tar with calamine | Not approved for prescribing | ||||
crotamiton | Joint formulary choice | ||||
difelikefalin | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA890 |
|||
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
Solution for injection | |||||
Kapruvia (Vifor Fresenius Medical Care Renal Pharma UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
doxepin | Not approved for prescribing | ||||
Doxepin cream not approved for vulvodynia
March 2022 - The JPG did not recommend the use of doxepin 5% cream for the treatment of vulvodynia due to the lack of safety and efficacy evidence to support use in this cohort of patients. |
|||||
hydroxyzine hydrochloride | Joint formulary choice | ||||
levocetirizine hydrochloride | Not approved for prescribing | ||||
Oral solution | |||||
Xyzal (UCB Pharma Ltd) | Not approved for prescribing | ||||
levomenthol | Not approved for prescribing | ||||
Skin / Bacterial skin infections | |||||
metronidazole | Joint formulary choice | ||||
mupirocin | Joint formulary choice | ||||
Nasal ointment | |||||
Bactroban (GlaxoSmithKline UK Ltd) | Joint formulary choice | ||||
silver sulfadiazine | Hospital only | ||||
Skin / Fungal skin infections | |||||
amorolfine | Joint formulary choice | ||||
Medicated nail lacquer | |||||
Amorolfine (Non-proprietary) | Joint formulary choice | ||||
Loceryl (Galderma (UK) Ltd) | Not approved for prescribing | ||||
benzoic acid with salicylic acid | Not approved for prescribing | ||||
chlorhexidine with nystatin | Not approved for prescribing | ||||
clotrimazole | Joint formulary choice | ||||
Liquid | |||||
Canesten (Bayer Plc) | Joint formulary choice | ||||
Spray | |||||
Canesten (Bayer Plc) | Joint formulary choice | ||||
Cutaneous cream | |||||
Clotrimazole (Non-proprietary) | Joint formulary choice | ||||
econazole nitrate | Not approved for prescribing | ||||
griseofulvin | Joint formulary choice | ||||
hydrocortisone with clotrimazole | Joint formulary choice | ||||
ketoconazole | Joint formulary choice | ||||
miconazole | Joint formulary choice | ||||
Spray | |||||
Daktarin (Johnson & Johnson Ltd) | Joint formulary choice | ||||
terbinafine | Joint formulary choice | ||||
Oral tablet | |||||
Terbinafine (Non-proprietary) | Joint formulary choice | ||||
Cutaneous cream | |||||
Terbinafine (Non-proprietary) | Joint formulary choice | ||||
Lamisil (Haleon UK Ltd) | Joint formulary choice | ||||
tioconazole | Not approved for prescribing | ||||
undecenoic acid with zinc undecenoate | Not approved for prescribing | ||||
Skin / Parasitic skin infections | |||||
benzyl benzoate | Not approved for prescribing | ||||
dimeticone | Joint formulary choice | ||||
Liquid | |||||
Hedrin (Thornton & Ross Ltd) | Joint formulary choice | ||||
Lyclear (Omega Pharma Ltd) | Joint formulary choice | ||||
Cutaneous spray solution | |||||
Hedrin (Thornton & Ross Ltd) | Joint formulary choice | ||||
ivermectin | Not approved for prescribing | ||||
malathion | Joint formulary choice | ||||
permethrin | Joint formulary choice | ||||
Liquid | |||||
Lyclear (Omega Pharma Ltd) | Joint formulary choice | ||||
Skin / Viral skin infections | |||||
aciclovir | Joint formulary choice |